Characteristics and medications of patients with rheumatoid arthritis (RA) with or without atherosclerotic cardiovascular disease (CVD) and with or without diabetes mellitus (DM)
| RA cases without atherosclerotic CVD | P value* | RA cases with atherosclerotic CVD | P value* | |||||||
| DM, n=1012 | No DM, n=8097 | DM, n=369 | No DM, n=1065 | |||||||
| Data available | Data available | Data available | Data available | |||||||
| n (%) | n (%) | n (%) | n (%) | |||||||
| Female, n (%) | 769 (76.0) | 1012 (100.0) | 6340 (78.3) | 8097 (100.0) | 0.094 | 217 (58.8) | 369 (100.0) | 655 (61.5) | 1065 (100.0) | 0.361 |
| Age (years), mean (SD) | 63.7 (11.9) | 1012 (100.0) | 58.3 (14.0) | 8097 (100.0) | <0.001 | 70.3 (9.1) | 369 (100.0) | 69.0 (11.2) | 1065 (100.0) | 0.200 |
| World region, n (%) | 1012 (100.0) | 8097 (100.0) | 369 (100.0) | 1065 (100.0) | ||||||
| Western Europe | 486 (48.0) | 3876 (47.9) | 129 (35.0) | 395 (37.1) | 0.175 | |||||
| Eastern Europe | 66 (6.5) | 640 (7.9) | 39 (10.6) | 150 (14.1) | ||||||
| North America | 409 (40.4) | 3068 (37.9) | 0.104 | 185 (50.1) | 515 (48.4) | |||||
| Asia | 51 (5.0) | 513 (6.3) | 16 (4.3) | 5 (0.5) | ||||||
| Ethnicity, n (%) | 970 (95.8) | 7632 (94.3) | 362 (98.1) | 1016 (95.4) | ||||||
| Asian | 59 (6.1) | 571 (7.5) | 17 (4.9) | 51 (5.0) | ||||||
| Black | 9 (0.9) | 36 (0.5) | 2 (0.6) | 3 (0.4) | ||||||
| White | 734 (75.7) | 6326 (82.9) | <0.001 | 319 (91.7) | 939 (92.4) | <0.001 | ||||
| White hispanic | 48 (4.9) | 222 (2.9) | 9 (2.5) | 9 (0.9) | ||||||
| Hispanic | 39 (4.0) | 0 (0.0) | 5 (1.4) | 0 (0.0) | ||||||
| Other | 81 (8.0) | 477 (6.3) | 10 (2.8) | 13 (1.3) | ||||||
| Hypertension, n (%) | 618 (61.6) | 1004 (99.2) | 2461 (30.5) | 8078 (99.8) | <0.001 | 304 (82.6) | 368 (99.7) | 691 (64.9) | 1065 (100.0) | <0.001 |
| Hyperlipidaemia, n (%) | 484 (48.3) | 1002 (99.0) | 1731 (21.7) | 7975 (98.5) | <0.001 | 253 (69.1) | 366 (99.2) | 531 (50.4) | 1054 (99.0) | <0.001 |
| Premature CVD in family, n (%) | 20 (5.1) | 395 (39.0) | 177 (5.7) | 3132 (38.7) | <0.001 | 14 (13.3) | 105 (28.5) | 54 (15) | 360 (33.8) | 0.671 |
| Medication, n (%) | ||||||||||
| Statins | 312 (47.2) | 661 (65.3) | 900 (16.0) | 5618 (69.4) | <0.001 | 198 (72.3) | 274 (74.3) | 433 (52.7) | 821 (77.1) | <0.001 |
| Other lipid-lowering agents | 33 (5.2) | 633 (62.5) | 102 (1.9) | 5354 (66.1) | <0.001 | 17 (6.3) | 268 (72.6) | 28 (3.5) | 793 (74.5) | 0.048 |
| Antihypertensive agents | ||||||||||
| ACE inhibitor or ARB-blocker | 311 (39.2) | 633 (62.5) | 883 (16.5) | 5352 (66.1) | <0.001 | 141 (52.6) | 268 (72.6) | 311 (39.2) | 793 (74.5) | <0.001 |
| Beta blocker | 123 (19.4) | 633 (62.5) | 678 (12.7) | 5355 (66.1) | <0.001 | 163 (60.8) | 268 (72.6) | 395 (49.7) | 794 (74.6) | <0.001 |
| Any antihypertensive agent | 392 (61.9) | 633 (62.5) | 1904 (35.6) | 5352 (66.1) | <0.001 | 235 (87.7) | 268 (72.6) | 605 (76.6) | 790 (74.2) | <0.001 |
| Insulin | 139 (22.0) | 633 (62.5) | 0 | 5354 (66.1) | 80 (30.0) | 267 (72.4) | 0 | 793 (74.5) | ||
| Oral diabetes medications | 394 (62.2) | 633 (62.5) | 0 | 5354 (66.1) | 139 (52.1) | 267 (72.4) | 0 | 793 (74.5) | ||
For categorical variables, valid percentages are reported.
Significant p values are highlighted in bold.
*.χ2 for frequencies and Mann-Whitney U test for continuous variables.
ARB, angiotensin receptor blocker.